Loading patent…
AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorsNicholas G Bazan, Julio Alvarez Builla Gomez
Estimating the term…
A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-α] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke. 1
A method to synthesis 6-(2-chlorophenyl)-9-[(4-methoxyphenyl)thiocarbamoyl]-1-methyl-7,8,9,10-tetrahydro-4H-pyrido[4′,3′:4,5]thieno[3,2-f]-1,2,4-triazolo[4,3-a]-1,4-diazepine, compound 1, comprising the steps of the following diagram:
A method of ameliorating or preventing in a mammal, the symptoms of diabetic retinopathy in a patient, comprising administering to the mammal a therapeutically effective amount of LAU-8080.
Dependencies are inferred from the claim text.